BlueWillow’s clinical-stage intranasal adjuvant and antigen delivery platform is the most advanced in development. The NanoVax^® platform (W₈₀5EC) is compatible with a broad array of viral, bacterial, and food antigens. With human safety established from multiple clinical trials, it elicits the three-pronged mucosal, cellular, and systemic immune response needed for robust protection against both symptomatic disease and transmission. BlueWillow’s vaccine pipeline includes candidates targeting H5N1 (bird flu), influenza (pandemic and seasonal), tuberculosis, covid, RSV, herpes simplex, and peanut allergy.